Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Thomas Müller. (2017) Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease. Expert Opinion on Pharmacotherapy 18:14, pages 1457-1465.
Read now
Read now
Ruxandra Julia Vorovenci & Angelo Antonini. (2015) The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease. Expert Review of Neurotherapeutics 15:12, pages 1383-1390.
Read now
Read now
Anne-Catherine Vijverman & Susan H Fox. (2014) New treatments for the motor symptoms of Parkinson’s disease. Expert Review of Clinical Pharmacology 7:6, pages 761-777.
Read now
Read now
Brenton A Wright & Cheryl H Waters. (2013) Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease. Expert Review of Neurotherapeutics 13:6, pages 719-729.
Read now
Read now
Robert A Hauser. (2012) IPX066: a novel carbidopa–levodopa extended-release formulation. Expert Review of Neurotherapeutics 12:2, pages 133-140.
Read now
Read now
Articles from other publishers (37)
P. S. Pharande, G. S. Rashinkar & D. M. Pore. (2023) Silica-grafted DBU-supported NiCl2: a sustainable heterogeneous catalyst for A3 coupling. Research on Chemical Intermediates 49:6, pages 2359-2382.
Crossref
Crossref
Unaiza Naeem, Abdul Rehman Arshad, Areesha Jawed, Farea Eqbal, Laiba Imran, Zayeema Khan & Farhat Ijaz. (2022) Glycolysis: The Next Big Breakthrough in Parkinson’s Disease. Neurotoxicity Research 40:6, pages 1707-1717.
Crossref
Crossref
Jiajia Li, Lei Li & Esmail Vessally. (2020)
Decarboxylative
A
3
‐coupling reactions: An overview
. Journal of the Chinese Chemical Society 68:1, pages 13-26.
Crossref
Crossref
Adrián Tóth, Zsófia Antal, Dániel Bereczki & Beáta Sperlágh. (2019) Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration. Neurochemical Research 44:10, pages 2413-2422.
Crossref
Crossref
Dasiel O. Borroto-Escuela & Kjell Fuxe. (2019) Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment. Journal of Neural Transmission 126:4, pages 455-471.
Crossref
Crossref
Neslihan Edeer Karaca, Guzide Aksu & Necil Kutukculer. 2019. Pediatric Immunology. Pediatric Immunology
327
331
.
Ashish Kumar Kakkar, Harmanjit Singh & Bikash Medhi. (2018) Old wines in new bottles: Repurposing opportunities for Parkinson's disease. European Journal of Pharmacology 830, pages 115-127.
Crossref
Crossref
Luiza R. Nazario, Rosane S. da Silva & Carla D. Bonan. (2017) Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches. Frontiers in Neuroscience 11.
Crossref
Crossref
Ana O. Pires, F.G. Teixeira, B. Mendes-Pinheiro, Sofia C. Serra, Nuno Sousa & António J. Salgado. (2017) Old and new challenges in Parkinson's disease therapeutics. Progress in Neurobiology 156, pages 69-89.
Crossref
Crossref
Hossein Sanjari Moghaddam, Ameneh Zare-Shahabadi, Farzaneh Rahmani & Nima Rezaei. (2017) Neurotransmission systems in Parkinson’s disease. Reviews in the Neurosciences 28:5, pages 509-536.
Crossref
Crossref
Hee J. Kim, Beom S. Jeon & Peter Jenner. 2017. Parkinson's Disease. Parkinson's Disease
295
343
.
Dasiel O. Borroto-Escuela, Manuel Narváez, Gemma Navarro, Rafael Franco & Kjell Fuxe. 2017. G-Protein-Coupled Receptor Dimers. G-Protein-Coupled Receptor Dimers
477
501
.
Thomas Müller. (2016) Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective. Neurodegenerative Disease Management 6:5, pages 385-398.
Crossref
Crossref
Gemma Navarro, Dasiel O. Borroto-Escuela, Kjell Fuxe & Rafael Franco. (2016) Purinergic signaling in Parkinson's disease. Relevance for treatment. Neuropharmacology 104, pages 161-168.
Crossref
Crossref
Yasaman Kianirad & Tanya Simuni. (2016) Novel Approaches to Optimization of Levodopa Therapy for Parkinson’s Disease. Current Neurology and Neuroscience Reports 16:4.
Crossref
Crossref
M. Angela Cenci-Nilsson & Per Odin. 2016. Parkinson's Disease. Parkinson's Disease
63
75
.
. 2016. Parkinson's Disease. Parkinson's Disease
1
92
.
Esmail Vessally. (2016) A new avenue to the synthesis of highly substituted pyrroles: synthesis from N-propargylamines. RSC Advances 6:22, pages 18619-18631.
Crossref
Crossref
Delia Preti, Pier Giovanni Baraldi, Allan R. Moorman, Pier Andrea Borea & Katia Varani. (2015)
History and Perspectives of A
2A
Adenosine Receptor Antagonists as Potential Therapeutic Agents
. Medicinal Research Reviews 35:4, pages 790-848.
Crossref
Crossref
Frank T Zindo, Jacques Joubert & Sarel F Malan. (2015) Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond. Future Medicinal Chemistry 7:5, pages 609-629.
Crossref
Crossref
E. A. Katunina, N. V. Titova, Yu. N. Bezdolny, R. K. Shykkerimov, M. G. Gasanov, S. G. Burd, A. V. Lebedeva & A. N. Boiko. (2015) Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 115:5, pages 34.
Crossref
Crossref
Catarina Gomes, Jimmy George, Jiang-Fan Chen & Rodrigo A. Cunha. 2015. The Adenosinergic System. The Adenosinergic System
81
99
.
Rui Daniel Prediger, Filipe Carvalho Matheus, Paulo Alexandre de Oliveira, Daniel Rial, Morgana Moretti, Ana Cristina Guerra de Souza, Aderbal Silva AguiarJr.Jr. & Rodrigo A. Cunha. 2015. The Adenosinergic System. The Adenosinergic System
183
205
.
Myroslava K. Romach, Kerri A. Schoedel & Edward M. Sellers. (2014) Human abuse liability evaluation of CNS stimulant drugs. Neuropharmacology 87, pages 81-90.
Crossref
Crossref
Ricardo Cabezas, Marcos Ãvila, Janneth Gonzalez, Ramon Santos El-BacháEliana Báez, Luis Miguel GarcÃa-Segura, Juan Camilo Jurado Coronel, Francisco Capani, Gloria Patricia Cardona-Gomez & George E. Barreto. (2014) Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease. Frontiers in Cellular Neuroscience 8.
Crossref
Crossref
Karen M. Smith, Susan E. Browne, Srinivasan Jayaraman, Carina J. Bleickardt, Lisa M. Hodge, Edward Lis, Leon Yao, Sunday L. Rittle, Nathalie Innocent, Deborra E. Mullins, George Boykow, Ian J. Reynolds, David Hill, Eric M. Parker & Robert A. Hodgson. (2014) Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice. European Journal of Pharmacology 728, pages 31-38.
Crossref
Crossref
Christoph Proschel, Jennifer L Stripay, Chung‐Hsuan Shih, Joshua C Munger & Mark D Noble. (2014)
Delayed transplantation of precursor cell‐derived astrocytes provides multiple benefits in a rat model of
P
arkinsons
. EMBO Molecular Medicine 6:4, pages 504-518.
Crossref
Crossref
Kjell Fuxe, Dasiel O Borroto-Escuela, Wilber Romero-Fernandez, Miklós Palkovits, Alexander O Tarakanov, Francisco Ciruela & Luigi F Agnati. (2013) Moonlighting Proteins and Protein–Protein Interactions as Neurotherapeutic Targets in the G Protein-Coupled Receptor Field. Neuropsychopharmacology 39:1, pages 131-155.
Crossref
Crossref
Fabrizio Stocchi. (2013) Therapy for Parkinson’s Disease: What is in the Pipeline?. Neurotherapeutics 11:1, pages 24-33.
Crossref
Crossref
Philippe Huot. 2014. Levodopa-Induced Dyskinesia in Parkinson's Disease. Levodopa-Induced Dyskinesia in Parkinson's Disease
147
169
.
Pierre Koch, Rhalid Akkari, Andreas Brunschweiger, Thomas Borrmann, Miriam Schlenk, Petra Küppers, Meryem Köse, Hamid Radjainia, Jörg Hockemeyer, Anna Drabczyńska, Katarzyna Kieć-Kononowicz & Christa E. Müller. (2013) 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. Bioorganic & Medicinal Chemistry 21:23, pages 7435-7452.
Crossref
Crossref
Joseph JankovicCara A Pecina & Alberto J Espay. 2013. Parkinson’s Disease: Medical and Surgical Treatment. Parkinson’s Disease: Medical and Surgical Treatment
43
60
.
Scott Kaplan & Daniel Tarsy. (2013) Initial Treatment of Parkinson’s Disease: An Update. Current Treatment Options in Neurology 15:4, pages 377-384.
Crossref
Crossref
Fernando L. Pagan & Jill Giordano Farmer. 2013. Handbook of Parkinson’s Disease. Handbook of Parkinson’s Disease
466
477
.
Cristina Miguelez, Stéphanie Morin, Audrey Martinez, Michel Goillandeau, Erwan Bezard, Bernard Bioulac & Jérôme Baufreton. (2012) Altered pallido‐pallidal synaptic transmission leads to aberrant firing of globus pallidus neurons in a rat model of Parkinson's disease. The Journal of Physiology 590:22, pages 5861-5875.
Crossref
Crossref
Werner Poewe, Philipp Mahlknecht & Joseph Jankovic. (2012) Emerging therapies for Parkinsonʼs disease. Current Opinion in Neurology 25:4, pages 448-459.
Crossref
Crossref
Alessandro Dalpiaz, Barbara Cacciari, Chiara Beatrice Vicentini, Fabrizio Bortolotti, Giampiero Spalluto, Stephanie Federico, Barbara Pavan, Fabrizio Vincenzi, Pier Andrea Borea & Katia Varani. (2012)
A Novel Conjugated Agent between Dopamine and an A
2A
Adenosine Receptor Antagonist as a Potential Anti-Parkinson Multitarget Approach
. Molecular Pharmaceutics 9:3, pages 591-604.
Crossref
Crossref